DECKERT, Jutta,DECKERT JUTTA,LEJEUNE, Pascale,LEJEUNE PASCALE,MAYO, Michele F,MAYO MICHELE F,PARK, Peter U,PARK PETER U
申请号：
ES11801669
公开号：
ES2694784T3
申请日:
2011.12.08
申请国别(地区):
ES
年份:
2018
代理人:
摘要：
Pharmacists, the antibody specially recognized including one, especially CD38 and Bortezmib. It is required that 1: a kind of preparation medicament, including a kind of antibody for specially recognizing CD38 and at least Bortezmib, in this antibody, this antibody has the ability to kill a CD38+cell by the poisoning toxin of antibody cell (ADICA) and cell. The x-ray attribute of mutation (CDC). 2.Advocate 2: antibody Section 1 being combined, wherein, antibody is a kind of antibody of hommization. 2.Advocate 3: " 2nd " advocates, in the antibody, the antibody includes one or more complementary determining areas, these regions have one or more complementary determining areas, this region is the selected amino acid sequence 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16 of the group. 17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36 and 81. 16th article: one manufacture clause, including :(a) packaging material, (b) combination of the special antibody for recognizing CD38 and at least Bortezmib, in this antibody, this antibody has the ability to kill a CD38+cell by infectiousness cytotoxicity. (CDC) label and omen contained in (c) this based packaging material show that the combination of this packaging is effective to treating cancer.
